Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...

In a head-to-head phase 3 trial presented at the 2024 World Conference on Lung Cancer (WCLC) – called HARMONi-2 – PD-1xVEGF bispecific ivonescimab cut the risk of disease progression or death ...